SK Biopharmaceuticals’s new anti-epileptic drug ‘Xcopri’ has brought in a total of ₩400 billion in upfront payments and milestone payments over the past 3 years. This is the largest amount of cash secured by a new drug that was licensed out by Korean pharmaceutical companies.

According to the Financial Supervisory Service on the 14th, SK Biopharmaceuticals signed a licensing deal with the Brazilian pharmaceutical company Eurofarma Laboratorios SA for its anti-epileptic drug Xcopri. Under the agreement, SK Biopharmaceuticals will receive an upfront payments of $15 million and up to $47 million in milestone payments which are paid when each phase of development, approval, etc. is completed. The comp